CD70 Protein, Human, Recombinant (hFc)

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

规格	价格/CNY		数量
100 μg	￥ 2,930	现货
200 μg	￥ 5,190	5日内发货
500 μg	￥ 10,980	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 2,930

现货

200 μg

￥ 5,190

5日内发货

500 μg

￥ 10,980

5日内发货

生物活性

Measured by its binding ability in a functional ELISA. Immobilized Human CD27 His at 2 μg/ml (100 μl/well) can bind Human CD70 hFc , the EC50 of Human CD70 hFc is 15-60 ng/mL.

TargetMol Bioactive

产品描述

种属	Human
表达系统	HEK293
标签	hFc
蛋白编号	A0A0U5JA32
别名	TNFSF7, CD27L, CD27LG, CD70 molecule
蛋白构建	A DNA sequence encoding the extracellular domain of human CD70 (NP_001243.1) (Gln 39-Pro 193) was fused with the Fc region of human IgG1 at the N-terminus via a polypeptide linker.
蛋白纯度	> 90 % as determined by SDS-PAGE
分子量	45.5 kDa (predicted)

内毒素	< 1.0 EU per μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
复溶方法	A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
存储	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy